(Q38011765)

27 August 2017

Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders (English)

1 reference

27 August 2017

1

Tadeusz Robak

1 reference

27 August 2017

2

Ewa Robak

1 reference

PubMed ID

22612424

27 August 2017

language of work or name

English

0 references

publication date

22 May 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

1 reference

27 August 2017

21

1 reference

27 August 2017

7

1 reference

27 August 2017

921-947

1 reference

Modulation of the Fcepsilon receptor I signaling by tyrosine kinase inhibitors: search for therapeutic targets of inflammatory and allergy diseases

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Expression of Bruton's tyrosine kinase protein within the B cell lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Btk dosage determines sensitivity to B cell antigen receptor cross-linking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Regulation of Btk by Src family tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Btk function in B cell development and response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Defective B cell development and function in Btk-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Primary B cell immunodeficiencies: comparisons and contrasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Bruton's tyrosine kinase as a drug discovery target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

An important role for Akt3 in platelet activation and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The SYK tyrosine kinase: a crucial player in diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Tyrosine kinase SYK: essential functions for immunoreceptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

PSGL-1 engagement by E-selectin signals through Src kinase Fgr and ITAM adapters DAP12 and FcR gamma to induce slow leukocyte rolling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Syk and pTyr'd: Signaling through the B cell antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

SYK inhibition and response prediction in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Design and synthesis of non-peptidic inhibitors for the Syk C-terminal SH2 domain based on structure-based in-silico screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Identification of the Syk kinase inhibitor R112 by a human mast cell screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Inhibition of eukaryote serine/threonine-specific protein kinases by piceatannol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Resveratrol-Cu(II) induced DNA breakage in human peripheral lymphocytes: implications for anticancer properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Syk-dependent mTOR activation in follicular lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

ER-27319, an acridone-related compound, inhibits release of antigen-induced allergic mediators from mast cells by selective inhibition of fcepsilon receptor I-mediated activation of Syk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Therapeutic prospect of Syk inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

SRC: a century of science brought to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Src kinase inhibitors: promising cancer therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Multiple roles of Lyn kinase in myeloid cell signaling and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Regulation of B-cell fate by antigen-receptor signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Imatinib sensitizes CLL lymphocytes to chlorambucil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The difference in biological properties between parental and v-Ha-ras transformed NIH3T3 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

A critical role for Lyn in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Human B lymphocytes and non-Hodgkin's lymphoma cells become polyploid in response to the protein kinase inhibitor SU6656.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Membrane-associated signaling in human B-lymphoma lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Inhibition of Src kinases combined with CD40 ligand blockade prolongs murine cardiac allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685650

10.1517/13543784.2012.685650

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22612424